Sign In
Buy DBVT
$13.63
-0.230 (-1.66%)
At Close: Jul 24, 2026
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
04:46pm, Thursday, 23'rd Jul 2026
DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
05:00pm, Friday, 17'th Jul 2026
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
07:26pm, Thursday, 16'th Jul 2026
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies Q2 Earnings Call Highlights
07:03pm, Thursday, 16'th Jul 2026
DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, wh
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
04:10pm, Thursday, 16'th Jul 2026
Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: F
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
04:01pm, Thursday, 16'th Jul 2026
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA fo
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
04:30pm, Tuesday, 14'th Jul 2026
Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
04:30pm, Monday, 06'th Jul 2026
AMF Regulated Information Châtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq S
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
09:42am, Tuesday, 30'th Jun 2026
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
04:30pm, Tuesday, 23'rd Jun 2026
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
09:01am, Monday, 15'th Jun 2026
DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
07:00am, Tuesday, 09'th Jun 2026
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, V
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
04:30pm, Friday, 05'th Jun 2026
Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M
